In Vitro Dynamic Visualization Analysis of Fluorescently Labeled Minor Capsid Protein IX and Core Protein V by Simultaneous Detection

Journal of Molecular Biology

Volumn 395, Issue 1, 2010, Pages 55-78

  Ugai, Hideyo ^a   Wang, Minghui ^a   Le, Long P ^b   Matthews, David A ^c   Yamamoto, Masato ^d   Curiel, David T ^a,e  

^a University of Alabama at Birmingham   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

adenovirus; fluorescent protein; imaging; pIX; pV

Indexed keywords

CAPSID PROTEIN; CAPSID PROTEIN IX; CORE PROTEIN; CORE PROTEIN V; ENHANCED GREEN FLUORESCENT PROTEIN; RED FLUORESCENT PROTEIN; UNCLASSIFIED DRUG;

ADENOVIRUS; ADENOVIRUS INFECTION; ARTICLE; CONTROLLED STUDY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SIGNAL DETECTION; VIROGENESIS; VIRUS DETECTION; VIRUS REPLICATION;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5; MIRIDAE;

EID: 70450237704     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.10.034     Document Type: Article

References (74)

1. Haj-Ahmad Y., and Graham F.L. Development of a helper-independent human adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase gene. J. Virol. 57 (1986) 267-274
2. Alemany R. Cancer selective adenoviruses. Mol. Aspects Med. 28 (2007) 42-58
3. Chiocca E.A. Oncolytic viruses. Nat. Rev. Cancer 2 (2002) 938-950
4. Nettelbeck D.M. Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer. J. Mol. Med. 86 (2008) 363-377
5. Russell S.J., and Peng K.W. Viruses as anticancer drugs. Trends Pharmacol. Sci. 28 (2007) 326-333
6. Ganly I., Kirn D., Eckhardt G., Rodriguez G.I., Soutar D.S., Otto R., et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6 (2000) 798-806
7. Kirn D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin. Biol. Ther. 1 (2001) 525-538
8. Ries S.J., and Brandts C.H. Oncolytic viruses for the treatment of cancer: current strategies and clinical trials. Drug Discov. Today 9 (2004) 759-768
9. Liu T.C., and Kirn D. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther. 15 (2008) 877-884
10. Cherubini G., Petouchoff T., Grossi M., Piersanti S., Cundari E., and Saggio I. E1B55K-deleted adenovirus (ONYX-015) overrides G1/S and G2/M checkpoints and causes mitotic catastrophe and endoreduplication in p53-proficient normal cells. Cell Cycle 5 (2006) 2244-2252
11. O'Shea C.C., Johnson L., Bagus B., Choi S., Nicholas C., Shen A., et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6 (2004) 611-623
12. Sauthoff H., Pipiya T., Heitner S., Chen S., Bleck B., Reibman J., et al. Impact of E1a modifications on tumor-selective adenoviral replication and toxicity. Mol. Ther. 10 (2004) 749-757
13. Parato K.A., Senger D., Forsyth P.A., and Bell J.C. Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer 5 (2005) 965-976
14. Le L.P., Everts M., Dmitriev I.P., Davydova J.G., Yamamoto M., and Curiel D.T. Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol. Imaging 3 (2004) 105-116
15. Le L.P., Le H.N., Dmitriev I.P., Davydova J.G., Gavrikova T., Yamamoto S., et al. Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. J. Natl. Cancer Inst. 98 (2006) 203-214
16. Le L.P., Le H.N., Nelson A.R., Matthews D.A., Yamamoto M., and Curiel D.T. Core labeling of adenovirus with EGFP. Virology 351 (2006) 291-302
17. Meulenbroek R.A., Sargent K.L., Lunde J., Jasmin B.J., and Parks R.J. Use of adenovirus protein IX (pIX) to display large polypeptides on the virion-generation of fluorescent virus through the incorporation of pIX-GFP. Mol. Ther. 9 (2004) 617-624
18. Parks R.J. Adenovirus protein IX: a new look at an old protein. Mol. Ther. 11 (2005) 19-25
19. Vellinga J., Van der Heijdt S., and Hoeben R.C. The adenovirus capsid: major progress in minor proteins. J. Gen. Virol. 86 (2005) 1581-1588
20. Crossland L.D., and Raskas H.J. Identification of adenovirus genes that require template replication for expression. J. Virol. 46 (1983) 737-748
21. Matsui T., Murayama M., and Mita T. Adenovirus 2 peptide IX gene is expressed only on replicated DNA molecules. Mol. Cell. Biol. 6 (1986) 4149-4154
22. Venkatesh L.K., and Chinnadurai G. Activation of the adenovirus 2 protein IX promoter by DNA replication in a transient expression assay. Nucleic Acids Res. 15 (1987) 2235-2250
23. Vales L.D., and Darnell Jr. J.E. Promoter occlusion prevents transcription of adenovirus polypeptide IX mRNA until after DNA replication. Genes Dev. 3 (1989) 49-59
24. Lee T.W., Blair G.E., and Matthews D.A. Adenovirus core protein VII contains distinct sequences that mediate targeting to the nucleus and nucleolus, and colocalization with human chromosomes. J. Gen. Virol. 84 (2003) 3423-3428
25. Ugai H., Borovjagin A.V., Le L.P., Wang M., and Curiel D.T. Thermostability/infectivity defect caused by deletion of the core protein V gene in human adenovirus type 5 is rescued by thermo-selectable mutations in the core protein X precursor. J. Mol. Biol. 366 (2007) 1142-1160
26. Chartier C., Degryse E., Gantzer M., Dieterle A., Pavirani A., and Mehtali M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 70 (1996) 4805-4810
27. Tang Y., Le L.P., Matthews Q.L., Han T., Wu H., and Curiel D.T. Derivation of a triple mosaic adenovirus based on modification of the minor capsid protein IX. Virology 377 (2008) 391-400
28. Takahashi E., Cohen S.L., Tsai P.K., and Sweeney J.A. Quantitation of adenovirus type 5 empty capsids. Anal. Biochem. 349 (2006) 208-217
29. Greber U.F., Willetts M., Webster P., and Helenius A. Stepwise dismantling of adenovirus 2 during entry into cells. Cell 75 (1993) 477-486
30. Flint S.J., Enquist L.W., Krug R.M., Racaniello V.R., and Skalka A.M. Virus cultivation, detection, and genetics. In: Flint S.J., Enquist L.W., Krug R.M., Racaniello V.R., and Skalka A.M. (Eds). Principles of Virology: Molecular Biology, Pathogenesis, and Control (2000), ASM Press, Washington, DC 24-56
31. Baens M., Noels H., Broeckx V., Hagens S., Fevery S., Billiau A.D., et al. The dark side of EGFP: defective polyubiquitination. PLoS ONE 1 (2006) e54
32. Li X., Zhao X., Fang Y., Jiang X., Duong T., Fan C., et al. Generation of destabilized green fluorescent protein as a transcription reporter. J. Biol. Chem. 273 (1998) 34970-34975
33. Kornuc M., Kliewer S., Garcia J., Harrich D., Li C., and Gaynor R. Adenovirus early region 3 promoter regulation by E1A/E1B is independent of alterations in DNA binding and gene activation of CREB/ATF and AP1. J. Virol. 64 (1990) 2004-2013
34. Hurst H.C., and Jones N.C. Identification of factors that interact with the E1A-inducible adenovirus E3 promoter. Genes Dev. 1 (1987) 1132-1146
35. Weeks D.L., and Jones N.C. Adenovirus E3-early promoter: sequences required for activation by E1A. Nucleic Acids Res. 13 (1985) 5389-5402
36. Holm P.S., Lage H., Bergmann S., Jurchott K., Glockzin G., Bernshausen A., et al. Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapy. Cancer Res. 64 (2004) 322-328
37. Steinwaerder D.S., Carlson C.A., and Lieber A. DNA replication of first-generation adenovirus vectors in tumor cells. Hum. Gene Ther. 11 (2000) 1933-1948
38. Nelson J.E., and Kay M.A. Persistence of recombinant adenovirus in vivo is not dependent on vector DNA replication. J. Virol. 71 (1997) 8902-8907
39. Matthews D.A. Adenovirus protein V induces redistribution of nucleolin and B23 from nucleolus to cytoplasm. J. Virol. 75 (2001) 1031-1038
40. Fukuda K., Abei M., Ugai H., Seo E., Wakayama M., Murata T., et al. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer. Cancer Res. 63 (2003) 4434-4440
41. Zhai Z.H., Nickerson J.A., Krochmalnic G., and Penman S. Alterations in nuclear matrix structure after adenovirus infection. J. Virol. 61 (1987) 1007-1018
42. Dunker R., and Brown D.T. Tubular subviral structure produced in adenovirus-infected KB cells. J. Virol. 31 (1979) 568-574
43. Ornelles D.A., and Shenk T. Localization of the adenovirus early region 1B 55-kilodalton protein during lytic infection: association with nuclear viral inclusions requires the early region 4 34-kilodalton protein. J. Virol. 65 (1991) 424-429
44. Ugai H., Yamasaki T., Hirose M., Inabe K., Kujime Y., Terashima M., et al. Purification of infectious adenovirus in two hours by ultracentrifugation and tangential flow filtration. Biochem. Biophys. Res. Commun. 331 (2005) 1053-1060
45. Ternovoi V.V., Le L.P., Belousova N., Smith B.F., Siegal G.P., and Curiel D.T. Productive replication of human adenovirus type 5 in canine cells. J. Virol. 79 (2005) 1308-1311
46. Le L.P., Li J., Ternovoi V.V., Siegal G.P., and Curiel D.T. Fluorescently tagged canine adenovirus via modification with protein IX-enhanced green fluorescent protein. J. Gen. Virol. 86 (2005) 3201-3208
47. Condit R.C. Principles of virology. In Fundamental Virology. In: Knipe D.M., and Howley P.M. (Eds). Fundamental Virology. 4th edit. (2001), Lippincott Williams and Wilkins, Philadelphia, PA 19-51
48. Maizel Jr. J.V., White D.O., and Scharff M.D. The polypeptides of adenovirus: I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36 (1968) 115-125
49. Saban S.D., Silvestry M., Nemerow G.R., and Stewart P.L. Visualization of alpha-helices in a 6-angstrom resolution cryoelectron microscopy structure of adenovirus allows refinement of capsid protein assignments. J. Virol. 80 (2006) 12049-12059
50. Fabry C.M., Rosa-Calatrava M., Moriscot C., Ruigrok R.W., Boulanger P., and Schoehn G. The C-terminal domains of adenovirus serotype 5 protein IX assemble into an antiparallel structure on the facets of the capsid. J. Virol. 83 (2009) 1135-1139
51. Shaner N.C., Steinbach P.A., and Tsien R.Y. A guide to choosing fluorescent proteins. Nat. Methods 2 (2005) 905-909
52. Vayda M.E., Rogers A.E., and Flint S.J. The structure of nucleoprotein cores released from adenovirions. Nucleic Acids Res. 11 (1983) 441-460
53. Matthews D.A., and Russell W.C. Adenovirus core protein V is delivered by the invading virus to the nucleus of the infected cell and later in infection is associated with nucleoli. J. Gen. Virol. 79 (1998) 1671-1675
54. Chatterjee P.K., Vayda M.E., and Flint S.J. Interactions among the three adenovirus core proteins. J. Virol. 55 (1985) 379-386
55. van Oostrum J., and Burnett R.M. Molecular composition of the adenovirus type 2 virion. J. Virol. 56 (1985) 439-448
56. Lehmberg E., Traina J.A., Chakel J.A., Chang R.J., Parkman M., McCaman M.T., et al. Reversed-phase high-performance liquid chromatographic assay for the adenovirus type 5 proteome. J. Chromatogr. B Biomed. Sci. Appl. 732 (1999) 411-423
57. 32P-labelled in vivo. J. Mol. Biol. 188 (1986) 23-37
58. Anderson C.W., Young M.E., and Flint S.J. Characterization of the adenovirus 2 virion protein, mu. Virology 172 (1989) 506-512
59. Meier O., Boucke K., Hammer S.V., Keller S., Stidwill R.P., Hemmi S., and Greber U.F. Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. J. Cell Biol. 158 (2002) 1119-1131
60. Cascallo M., Capella G., Mazo A., and Alemany R. Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Res. 63 (2003) 5544-5550
61. Thimmappaya B., Weinberger C., Schneider R.J., and Shenk T. Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection. Cell 31 (1982) 543-551
62. Chee-Sheung C.C., and Ginsberg H.S. Characterization of a temperature-sensitive fiber mutant of type 5 adenovirus and effect of the mutation on virion assembly. J. Virol. 42 (1982) 932-950
63. Bhat B.M., Brady H.A., and Wold W.S. Virus deletion mutants that affect a 3′ splice site in the E3 transcription unit of adenovirus 2. Mol. Cell. Biol. 5 (1985) 2405-2413
64. Mahr J.A., Boss J.M., and Gooding L.R. The adenovirus e3 promoter is sensitive to activation signals in human T cells. J. Virol. 77 (2003) 1112-1119
65. Garcia J., Wu F., and Gaynor R. Upstream regulatory regions required to stabilize binding to the TATA sequence in an adenovirus early promoter. Nucleic Acids Res. 15 (1987) 8367-8385
66. Bett A.J., Prevec L., and Graham F.L. Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol. 67 (1993) 5911-5921
67. Knipe D.M., Samueal C.E., and Palese P. Virus-host cell interactions. In: Knipe D.M., and Howley P.M. (Eds). Fundamental Virology. 4th edit. (2001), Lippincott Williams and Wilkins, Philadelphia, PA 133-170
68. Webster A., Russell S., Talbot P., Russell W.C., and Kemp G.D. Characterization of the adenovirus proteinase: substrate specificity. J. Gen. Virol. 70 (1989) 3225-3234
69. Ruzindana-Umunyana A., Imbeault L., and Weber J.M. Substrate specificity of adenovirus protease. Virus Res. 89 (2002) 41-52
70. Stewart P.L. Adenovirus structure. In: Curiel D.T., and Douglas J.T. (Eds). Adenoviral Vectors for Gene Therapy (2002), Academic Press, London, UK 1-18
71. Fallaux F.J., Kranenburg O., Cramer S.J., Houweling A., Van Ormondt H., Hoeben R.C., and Van Der Eb A.J. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum. Gene Ther. 7 (1996) 215-222
72. Belousova N., Korokhov N., Krendelshchikova V., Simonenko V., Mikheeva G., Triozzi P.L., et al. Genetically targeted adenovirus vector directed to CD40-expressing cells. J. Virol. 77 (2003) 11367-11377
73. Kanegae Y., Makimura M., and Saito I. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn. J. Med. Sci. Biol. 47 (1994) 157-166
74. Saito I., Oya Y., Yamamoto K., Yuasa T., and Shimojo H. Construction of nondefective adenovirus type 5 bearing a 2.8-kilobase hepatitis B virus DNA near the right end of its genome. J. Virol. 54 (1985) 711-719